EuroBiotech: More Articles of Note

Newspapers

> Alligator Bioscience entered into a bispecific codevelopment pact with Aptevo Therapeutics. The candidate is based on Alligator's first generation bispecific antibody, ATOR-1016. Release

> E-Therapeutics decided to focus its resources on two immuno-oncology programs after reviewing its operation. The move means e-Therapeutics will try to outlicense other programs. Statement 

> Antabio secured up to up to $8.9 million non-dilutive funding from CARB-X, a public-private antibiotic R&D partnership. The French biotech will use the money to take its treatment for chronic Pseudomonas infections in cystic fibrosis patients up to the end of phase 1. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> The London School of Hygiene and Tropical Medicine named LifeArc as its technology transfer partner. The agreement tasks LifeArc, the organization formerly known as MRC Technology, with maximizing the value of the school’s research. Statement  

> N4 Pharma signed up Bio-Images Drug Delivery to run an early-phase trial of its reformulations of sildenafil, the active ingredient in Pfizer’s Viagra. The trial is designed to tee N4 up to run a larger trial of what it thinks are faster and longer acting erectile dysfunction drugs. Release

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.